Cordis: Overlapping Cypher stents more effective than overlapping bare metal stents

By Elaine Rigoli

Tampa, Fla., July 17 - Cordis Corp. said Monday that a pooled analysis of five clinical trials found that patients who required treatment with two or more overlapping stents for long artery blockages had lower rates of re-blockage, lower rates of re-treatment and less arterial narrowing when receiving Cypher sirolimus-eluting coronary stents than when receiving bare metal stents.

The patients also experienced a lower incidence of heart attacks and no increase in blood clots.

According to the pooled analysis, patients treated with overlapping Cypher stents had a heart attack rate that was 38% lower at the 30-day follow-up and 52% lower at the one-year follow-up, compared with those treated with bare metal stents.

As stent overlap is a common event, the company said this data provides important assurances to the interventional cardiology community regarding the safety of the Cypher stent.

Located in Miami Lakes, Fla., Cordis, a Johnson & Johnson company, develops interventional vascular technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.